Dynamic induction of pro-angiogenic milieu after transplantation of marrow-derived mesenchymal stem cells in experimental myocardial infarction

Rahbarghazi‬, Reza; Nassiri, Seyed Mahdi; Ahmadi, Seyed Hossein; Mohammadi, Elham; Rabbani, Shahram; Araghi, Atefeh; Hosseinkhani, Hossein

doi:10.1016/j.ijcard.2014.03.008

Cited by 76 publications

(56 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Soluble factors secreted by MSCs such as VEGF, Ang‐1, insulin‐like growth factor‐1, epidermal growth factor, stromal cell‐derived factor 1α, and basic fibroblast growth factor (bFGF) have also been reported to enhance the tissue regeneration, vascular density, and cardiomyocyte karyokinesis, leading to a decrease in the scar tissue . Rahbarghazi et al suggested that the activation of VEGF signaling can induce an angiogenesis‐promoting milieu after BM‐MSC injection into the peri‐infarct area. Aiming at a clear indication of which factors could account for the human umbilical cord tissue‐derived MSCs‐mediated beneficial effects in MI murine model, it is concluded that the expression of angiogenesis‐associated transcripts (subtypes of VEGF, Angs, HGF, C‐met, bFGF, transforming growth factor beta, and platelet‐derived growth factor alpha polypeptide β) is high .…”

Section: Discussionmentioning

confidence: 99%

Comparing the effects of MSCs and CD34+ cell therapy in a rat model of myocardial infarction

et al. 2016

View full text Add to dashboard Cite

Stem cell therapy is considered as a promising approach in the treatment of myocardial infarction (MI). This study was designed as a comparison of human umbilical cord blood (HUCB)-derived CD341 and HUCB-derived MSCs for the repair of cardiac tissue by induction of the angiogenesis. Forty-eight male rats were randomized into four groups: sham-operated group, MI group, MSCs-treated group, and CD341 cellstreated group. After 4 weeks, the rats were sacrificed. All sections from left ventricles of all groups were subjected to hematoxylin & eosin, Masson's trichrome, and immunohistochemical stains (CD133, CD44, and a-smooth muscle actin). RNA was extracted for gene expression of the angiogenic markers. A significant reduction of the infarct size and the amplitude of T-wave in the CD341 cells-treated group when compared with the MSCs-treated group were determined. Histologically, the MI group showed scar tissue, congested blood capillaries around the infarcted area, some necrotic cells, and inflammatory cells. Administration of either MSCs or CD341 cells had a therapeutic potential to induce regenerative changes in the myocardium with better results in CD341cells-treated group. Quantitative RT-PCR analysis revealed a significant increase in the expression of vascular endothelial growth factor (VEGF), VEGFR-2, Ang-1, and Tie-2 and a significant decreased expression of Ang-2 in stem cells transplanted groups when compared with the noncell transplanted hearts. A significant increase of VEGF, VEGFR-2, Ang-1, and Tie-2 expression in the group receiving CD341 cells than those receiving MSCs was found. Finally, there was an upregulation of both human VEGF and human hypoxia-inducible factor 1a in the infarcted hearts treated by CD341 cells than that treated by MSCs. We first revealed a superior efficacy of CD341 cells when compared with MSCs in induction of regenerative changes in the MI model. Both cell therapies may repair the damaged heart tissue primarily by secretion of proangiogenic factors that induce the angiogenesis and activate the angiogenesis signaling pathway. V C 2016 IUBMB Life, 68(5): [343][344][345][346][347][348][349][350][351][352][353][354] 2016

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing the effects of MSCs and CD34+ cell therapy in a rat model of myocardial infarction

et al. 2016

View full text Add to dashboard Cite

show abstract

“…24 However, it was MSCs, either or not transfected with pVEGF, that promoted the highest arteriogenic response. It has been reported that MSCs induce arteriolar growth in animal models of ischemic heart disease, 25,26 an effect attributed to the paracrine action of released factors and signaling molecules. 27 In fact, the secretome of MSCs include growth factors known to induce migration and proliferation of smooth muscle cells, like fibroblast gowth factor-1, hepatocyte growth factor and platelet-derived growth factor.…”

Section: Microvascular Proliferationmentioning

confidence: 99%

Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction

et al. 2015

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) are cardioprotective in acute myocardial infarction (AMI). Besides, we have shown that intramyocardial injection of plasmid-VEGF(165) (pVEGF) in ovine AMI reduces infarct size and improves left ventricular (LV) function. We thus hypothesized that MSCs overexpressing VEGF(165) (MSCs-pVEGF) would afford greater cardioprotection than non-modified MSCs or pVEGF alone. Sheep underwent an anteroapical AMI and, 1 week later, received intramyocardial MSCs-pVEGF in the infarct border. One month post treatment, infarct size (magnetic resonance) decreased by 31% vs pre-treatment. Of note, myocardial salvage occurred predominantly at the subendocardium, the myocardial region displaying the largest contribution to systolic performance. Consistently, LV ejection fraction recovered to almost its baseline value because of marked decrease in end-systolic volume. None of these effects were observed in sheep receiving non-transfected MSCs or pVEGF. Although myocardial retention of MSCs decreased steeply over time, the treatment induced significant capillary and arteriolar proliferation, which reduced subendocardial fibrosis. We conclude that in ovine AMI, allogeneic VEGF-overexpressing MSCs induce subendocardial myocardium salvage through microvascular proliferation, reducing infarct size and improving LV function more than non-transfected MSCs or the naked plasmid. Importantly, the use of a plasmid rather than a virus allows for repeated treatments, likely needed in ischemic heart disease.

show abstract

“…Tissue regeneration can be achieved by the following three key steps: Cell proliferation, cell seeding in a suitable scaffold, and the maintenance of the differentiation phenotype of the engineered tissues [1,60]. The property of 3D scaffolding biomaterials for cell attachment is one of the major factors contributing their morphology, proliferation, functions, and the subsequent tissue organization [45,54,61,62,63,64,65,66]. The last requisite is difficult to combine with the high porosity in volume of the material.…”

Section: Development Of Tissue Engineering In 3d Modelsmentioning

confidence: 99%

Development of 3D in Vitro Technology for Medical Applications

Hosseinkhani

2014

IJMS

Self Cite

View full text Add to dashboard Cite

In the past few years, biomaterials technologies together with significant efforts on developing biology have revolutionized the process of engineered materials. Three dimensional (3D) in vitro technology aims to develop set of tools that are simple, inexpensive, portable and robust that could be commercialized and used in various fields of biomedical sciences such as drug discovery, diagnostic tools, and therapeutic approaches in regenerative medicine. The proliferation of cells in the 3D scaffold needs an oxygen and nutrition supply. 3D scaffold materials should provide such an environment for cells living in close proximity. 3D scaffolds that are able to regenerate or restore tissue and/or organs have begun to revolutionize medicine and biomedical science. Scaffolds have been used to support and promote the regeneration of tissues. Different processing techniques have been developed to design and fabricate three dimensional scaffolds for tissue engineering implants. Throughout the chapters we discuss in this review, we inform the reader about the potential applications of different 3D in vitro systems that can be applied for fabricating a wider range of novel biomaterials for use in tissue engineering.

show abstract

Dynamic induction of pro-angiogenic milieu after transplantation of marrow-derived mesenchymal stem cells in experimental myocardial infarction

Cited by 76 publications

References 64 publications

Comparing the effects of MSCs and CD34+ cell therapy in a rat model of myocardial infarction

Comparing the effects of MSCs and CD34+ cell therapy in a rat model of myocardial infarction

Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction

Development of 3D in Vitro Technology for Medical Applications

Contact Info

Product

Resources

About